Panacea Index Logo

Command Palette

Search for a command to run...

Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults.

Clinical chemistry
December 1, 2019
Karen H Costenbader et al. (10 authors)
Journal ArticleRandomized Controlled TrialResearch Support, N.I.H., ExtramuralHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine whether vitamin D and marine ω-3 fatty acid (n-3 FA) supplementation reduces systemic inflammation biomarkers in older adults.

Results Summary

The study found that neither vitamin D nor n-3 FA supplementation over one year significantly reduced inflammation biomarkers (IL-6, TNFR2, hsCRP).

Population

Women ≥55 and men ≥50 years of age.

Effective Dosage

1 g/day of n-3 FA.

Duration

1 year.

Interactions

None mentioned.

Extracted Claims (7)
InterventionDirectionEndpointPopulationDosageImpactClaim #
vitamin D (2000 IU/day)
increase
25-OH vitamin D
women ≥55 and men ≥50 years of age
39%
rose
#1
n-3 FA (1 g/day)
increase
n-3 FA
women ≥55 and men ≥50 years of age
55%
rose
#2
vitamin D (2000 IU/day)
increase
IL-6
women ≥55 and men ≥50 years of age
8.2%
resulted in 8.2% higher
#3
vitamin D (2000 IU/day)
no change
biomarkers
women ≥55 and men ≥50 years of age
-
neither supplement reduced
#4
n-3 FA (1 g/day)
no change
biomarkers
women ≥55 and men ≥50 years of age
-
neither supplement reduced
#5
vitamin D (2000 IU/day)
no change
biomarkers of inflammation
women ≥55 and men ≥50 years of age
-
neither supplement decreased
#6
n-3 FA (1 g/day)
no change
biomarkers of inflammation
women ≥55 and men ≥50 years of age
-
neither supplement decreased
#7
Abstract

BACKGROUND: Observational studies suggest vitamin D and marine ω-3 fatty acid (n-3 FA) supplements are associated with lower systemic inflammation. However, past trials have been inconsistent. METHODS: The randomized, double-blind, placebo-controlled VITamin D and OmegA-3 TriaL (VITAL) tested vitamin D (2000 IU/day) and/or n-3 FA (1 g/day) supplementation in a 2 × 2 factorial design among women ≥55 and men ≥50 years of age. We assessed changes in interleukin (IL)-6, tumor necrosis factor receptor 2 (TNFR2), and high-sensitivity C-reactive protein (hsCRP) concentrations from baseline to 1 year among participants randomized to vitamin D + n-3 FA (392), vitamin D (392), n-3 FA (392), or placebo only (385). Geometric means and percent changes were compared, adjusting for baseline factors. RESULTS: Baseline characteristics were well balanced. In the active arms, 25-OH vitamin D rose 39% and n-3 FA rose 55% vs minimal change in placebo arms. Neither supplement reduced biomarkers at 1 year. Vitamin D resulted in 8.2% higher IL-6 (95% CI, 1.5%-15.3%; adjusted CONCLUSIONS: In this large sample from a population-based randomized controlled trial, neither vitamin D nor n-3 FA supplementation over 1 year decreased these biomarkers of inflammation. CLINICALTRIALSGOV IDENTIFIER: NCT01169259; NCT01351805.

Medical Subject Headings (MeSH)
AgedBiomarkersC-Reactive ProteinDietary SupplementsDouble-Blind MethodFatty Acids, Omega-6FemaleHumansInflammationInterleukin-6Longitudinal StudiesMaleMiddle AgedReceptors, Tumor Necrosis Factor, Type IIUnited StatesVitamin D
Study Links
Quality Scores
SafetyNot Assessed
Efficacy20/10
Quality85/10
Citation Metrics
Total Citations22
Citations/Year3.7
Relative Citation Ratio1.02
NIH Percentile50.8%
Research Impact Scores
APT Score0.75
Weight Score2.38
Normalized Score0.45
Related Supplements